Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis

Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis2018-01-17T17:03:58-05:00

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial2018-01-17T17:03:58-05:00

Design of effective immunotherapy for human autoimmunity

Design of effective immunotherapy for human autoimmunity2018-01-17T17:03:46-05:00

Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses

Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses2018-01-17T17:03:38-05:00

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis2018-01-17T17:03:38-05:00

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?2018-01-17T17:03:38-05:00

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring2018-01-17T17:03:31-05:00

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis2018-01-17T17:03:31-05:00

Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study2018-01-17T17:03:31-05:00

The Janus face of CNS-directed autoimmune response: a therapeutic challenge

The Janus face of CNS-directed autoimmune response: a therapeutic challenge2018-01-17T17:03:31-05:00